His prior experience also includes positions at MedImmune LLC, where he was Head of Global R&D, and at Bristol-Myers Squibb. November 2016 . Company status Active Company type Private limited Company Incorporated on 21 July 2014. When it joined the programme, the team was looking for seed funding for the proof-of-concept and to widen their network. There are currently 6 active directors according to the latest confirmation statement submitted on 21st July 2020. Cath graduated with BSc Hons in Genetics and Cell Biology from University of Manchester, UK, and a PhD in Biochemistry and Applied Molecular Biology from UMIST, UK. DJS ANTIBODIES – MEDICAL SCIENCES INTERN. In 2003, he joined Takeda Pharmaceutical Company where he built Takeda Ventures, Inc. (TVI), one of the first truly strategic Pharma corporate venture capital units. DJS utilises its proprietary HEPTAD technology, and its ability to discover leads against previously intractable GPCR targets, to discover and develop novel first-in-class therapeutic antibodies against key drivers of inflammatory disease. She also lectures at the London School of Hygiene and Tropical Medicine, sits on the strategic advisory board of the EPSRC Prosperity Partnership and has published over 60 articles in peer reviewed journals. J Geriatr Psychiatry Neurol. Separate to the Seed Fund, LifeArc has a Philanthropic Fund which provides grants to support medical research projects focused on the translation of rare diseases research. David Llewellyn. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.” He was formerly Head of Lead Discovery and Antibody Technologies within GSKs Biopharm R&D unit, where he led multidisciplinary project teams from start of discovery through to clinical candidate selection and beyond, working with a range of antibody formats and modalities including bispecifics. Founded in 2015, we’ve raised over $600M of evergreen capital, building on Oxford’s renowned research legacy, to create a leading science and technology ecosystem and home for entrepreneurs. In a research career spanning 30 years, Michael has worked across academic, biotech and pharmaceutical industries, specialising in protein and antibody engineering. Ongoing collaboration extended for another 12 months and successfully progresses into late stage hit-to-lead optimisation phase Cambridge…, A new COVID-19 drug screening and resistance hub will be established in Scotland, based at the MRC-University…, LifeArc to fund two post-doctoral fellowships focused on drug discovery In November 2020, LifeArc initiated a new…, LifeArc is a charity registered with the Charity Commission for England and Wales no. https://lnkd.in/d96kSzy #innovation #biotech #amazingteam #cbas2020 If you're looking to be surrounded by fantastic people and join an exciting team working on the cutting edge of drug discovery, get in touch! David Llewellyn . OX25 5HD. At DJS, we are developing a technology for isolating functional monoclonal antibodies against multi-pass integral membrane proteins such as GPCRs and ion channels. David Llewellyn Director of Marketing at supersmile New York, NY. David Llewellyn. Prior to joining Atlas, Uciane was the Director of BD and Strategy at Compass Therapeutics, a US-based clinical stage I-O/immunology company which launched in 2015 with a $132M Series A led by F-Prime and Orbimed. Lara likes a challenge, and so is keen to apply her skills to the field of drug discovery. In partnership with the University of Oxford, OSI creates fundamental technology companies, built on science. Amgen Ventures provides emerging biotechnology companies with financial and other resources to develop pioneering discoveries focused on human therapeutics. Epidemiological observations have long indicated that immunity against SM is acquired relatively rapidly, but prospective studies to investigate its immunological basis are logistically challenging and have rarely been undertaken. Dr David Llewellyn received his PhD in Clinical Medicine at the University of Oxford in 2014. We believe our approach will enhance value to all stakeholders and benefit patients around the world. David is the CEO and Co-Founder of DJS Antibodies. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. Company Overview for DJS ANTIBODIES LTD (09140967) Filing history for DJS ANTIBODIES LTD (09140967) People for DJS ANTIBODIES LTD (09140967) More for DJS ANTIBODIES LTD (09140967) ... David Llewellyn, Cherwell Innovation Centre, 77 Heyford … DJS ANTIBODIES LTD (09140967) Company status Active Correspondence address David Llewellyn, Cherwell Innovation Centre, 77 Heyford Park, Upper Heyford, Bicester, Oxfordshire, OX25 5HD. She thrives in fast-paced environments and working in a close-knit team. Position. Position. At DJS Antibodies equality, diversity and inclusion are really important to us. He cut his drug discovery teeth in the laboratory of Nobel Laureate Professor Sir James Black at the Wellcome Research Laboratories, subsequently working under the direction of Sir Salvador Moncada on serotonin receptor biology, which led to two IND candidate molecules, one of which - Zolmitriptan (Zomig®) – was launched in 1997 for migraine acute treatment. Post investment, we support our partner companies in strategically approaching the Asian market, allowing their products to achieve a global footprint. In this episode of Cheeky Scientist Radio, we interview Dr. David Llewellyn, who is the CEO of DJS Antibodies, a successful R&D startup company. Having originally come from the sunny shores of Australia, David came to the UK to complete a PhD at the University of Oxford’s Jenner Institute supported by a Rhodes Scholarship. David Llewellyn CEO at DJS Antibodies Greater Oxford Area. Features. David has more than 10 years’ experience in evolutionary immunology, antibody characterisation and myeloid cell biology, and he leads the team in our pursuit to create world changing antibody therapeutics. They have a breakthrough technology which overcomes this hurdle – revolutionising drug development. DJS Antibodies has developed HEPTAD, a novel platform for antibody discovery which was built to overcome the challenges associated with discovering therapeutic quality antibodies to intractable G-protein coupled receptor (GPCR) targets. In 2015 DJS Antibodies founded upon a vision of creating the next generation of antibody therapeutics. Our success allows us to explore new approaches to stimulate and fund translation. We are looking to recruit a motivated person with a broad interest in disease biology and drug development. Throughout her studies, she developed an interest in disease biology and practical laboratory science. brettwhatmough September 17, 2019. Accounts. David remains committed to promoting values of equality and diversity throughout DJS and more broadly. DJS Antibodies is an exemplar of the type of company we are trying to support—high-quality science, great scientists, strong start-up management all addressing a significant unmet patient need.”, Surinder MaanCommunications Manager, LifeArcsurinder.maan@lifearc.org. 2698321 incorporated in England and Wales. Pauline has a PhD in Immunology from the University of Pretoria and an MSc in microbial genetics from the University of the Witwatersrand. www.djsantibodies.com . As a research associate at DJS, Lara is responsible for performing a wide variety of lab tasks including cell culture, protein expression and purification, cell-based assays, and data analysis. He's an avid cricket and football fan and spends his spare time getting out on the water. Megan is motivated to pursue a career in drug discovery due to the opportunity to make a positive impact in science, and to be part of an innovative industry aiming to develop new medicines. See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. BioMe Oxford. Since January 2016 she has provided consultancy services to several biotech companies and has worked with the DJS team since 2018. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. In 2014, he co-founded DJS antibodies with Dr Joe Illingworth and works full-time in the company as CEO. David Llewellyn CEO at DJS Antibodies Greater Oxford Area. David has more than 10 years’ experience in evolutionary immunology, antibody characterisation and myeloid cell biology, and he leads the team in our pursuit to create world changing antibody therapeutics. He was a leader in the establishment of HEPTAD, the mAb discovery engine at the heart of DJS, and now oversees all R&D activities within the company. Developer of novel therapeutic monoclonal antibodies designed to target G-protein-coupled receptors (GPCRs). View David Llewellyn’s profile on LinkedIn, the world’s largest professional community. For more information, please visit www.amgenbd.com. After studying Joe worked as an academic on antibody induction and vaccination. How to Apply Please send a CV and cover letter by email to david.llewellyn@djsantibodies.com. in Chemistry from Lancaster University and a D.Phil. Graeme then moved to the USA joining Roche Bioscience as the Head of Molecular Pharmacology and VP of CNS R&D, participating in the advancement of two further molecules through IND. We are looking to recruit a motivated person with a broad interest in disease biology and drug development. John Haurum is a Non-executive Director in various European biotech companies (Synklino, Neophore, Storm, Agomab, Synact). She currently contributes towards the day-to-day running of the lab, development of new assays and management of our high-throughput antibody screening programmes. The company was founded in 2014 and is headquartered in Bicester, United Kingdom. He loves discovery, and so is motivated by the pursuit of developing totally novel therapeutics. We View David Llewellyn’s profile on LinkedIn, the world’s largest professional community. We developed HEPTAD, a revolutionary platform for antibody discovery, and now use this to create novel therapeutics that will have a meaningful impact on the lives of patients. Serum 25-hydroxyvitamin D concentration and cognitive impairment. View the profiles of professionals named "David Llewellyn" on LinkedIn. ... David currently acts as the CEO of the Oxford based biotech company DJS Antibodies, which designs and discovers novel therapeutic monoclonal antibodies against … David Llewellyn Director of Marketing at supersmile New York, NY. He loves discovery, and so is motivated by the pursuit of developing totally novel therapeutics. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Building a pipeline of unique assets enabled by a world-leading platform for antibody discovery. Epidemiological observations have linked increased host iron with malaria susceptibility, and perturbed iron handling has been hypothesized to contribute to the potentially life-threatening anemia that may accompany blood-stage malaria infection. David Llewellyn. David ... 294 others named David Llewellyn are on LinkedIn See others named David Llewellyn Privacy Policy. During his career Michael has authored more than 30 scientific papers and is a named inventor on a number of patents. SC037861. Life Sciences . Im Profil von David Llewellyn sind 10 Jobs angegeben. We match scientists with experienced entrepreneurs and patient capital to turn idea to impact, discovery to company. Sehen Sie sich das Profil von David Llewellyn im größten Business-Netzwerk der Welt an. Prior to Compass, she spent 5 years working with large-small cap biopharma companies in Boston as a commercial strategy consultant. Joe loves working in a small and focussed team to solve problems creatively. More for DJS ANTIBODIES LTD (09140967) Registered office address David Llewellyn, Cherwell Innovation Centre 77 Heyford Park, Upper Heyford, Bicester, Oxfordshire, OX25 5HD . Severe malaria (SM) is a life-threatening complication of infection with Plasmodium falciparum. Discovering new medicines is extremely difficult and most traditional methods fail. Early work, funded by Johnson&Johnson, has shown an unprecedented See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. DJS Antibodies. In a past life, David was a competitive kayaker, most often found half way down a waterfall, though now is more likely to be found watching water fall onto his struggling vegetable garden. Uciane joined OSI as a Principal in December 2019. | © LifeArc 2021, Annual Report and Accounts April-December 2019, Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration, LifeArc funds COVID-19 drug screening hub at the University of Glasgow, LifeArc and Cleveland Clinic collaborate to advance early stage research towards patients. DJS’ vision is to create safe, efficacious therapeutics that improve the lives of people with chronic inflammatory conditions. When she is not working, Megan enjoys walking in the countryside with her springer spaniel, cycling, skiing, painting and baking. She was previously an investor and EIR at the US-based fund, Atlas Venture, where she focussed on company creation, early-stage investing, and operations within Atlas portfolio companies. There are 200+ professionals named "David Llewellyn", who use LinkedIn to exchange information, ideas, and opportunities. Previously, Dr. Kiener was President and Co-founder of Zyngenia Inc, a monoclonal antibody company developing drugs for oncology and inflammatory diseases. We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.”, David Holbrook, Head of Seed Fund, LifeArc said: “The LifeArc Seed Fund is delighted to be supporting DJS Antibodies on its work on GPCR antibody targets and helping translate the science on the next step towards the patient. PubMed. Chief among these is his involvement with DJS where, since 2015, he has shared with the founding team the inevitable thrills and spills of innovating new medicines. Pauline Lukey is a drug discovery and development professional with 20 years of experience at GlaxoSmithKline R&D. Vitamin D deficiency is associated with low mood and worse cognitive performance in … CEO. Leave a Reply Cancel Reply. This funding round will support the development of two candidate antibody therapeutics including an antibody therapeutic for chronic kidney disease (CKD), a long-term condition that leads to the irreversible and progressive loss of kidney function. Joe is the CSO and Co-Founder of DJS Antibodies. Before joining DJS Lara completed an MRes in Biomedical Research at Imperial College. Contact: David Llewellyn (CEO) david.llewellyn@djsantibodies.com. Llewellyn DJ, Langa KM, Lang IA. 77 Heyford Park, David is the CEO and Co-Founder of DJS Antibodies. Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a company focused on developing antibody-drug conjugates. We invest in Life Sciences, Deep Tech, Healthtech, AI and Software to create companies taking on challenges like diagnosis and treatment of disease and cancer, hyper resolution microscopy, renewable energy, drones, nuclear fusion and quantum computing. Head to Head with DJS Antibodies. We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.” He shares his secrets to success and provide us with insight into life in a startup. David Llewellyn, DJS Antibodies. David Llewellyn, Co-founder and CEO of DJS Antibodies said: “We’re very excited to start working with LifeArc and such a strong group of investors. Startup R&D Positions (Cheeky Scientist Radio). DJS Antibodies is an Oxford based biotechnology company founded with support from Johnson & Johnson Innovation and Oxford Sciences Innovation. Huge congratulations to the DJS Antibodies team who won the Innovation Award at the 2020 Cherwell Business Awards on Friday. Joe holds a BSc in Biochemistry from Imperial College London and a PhD in antibody discovery and characterisation from the University of Oxford. He retired as President & CEO of TVI in 2017 and now maintains a portfolio of advisory and non-executive Board roles in early stage biotech in USA, Europe and Japan. All rights reserved. The LifeArc Seed Fund was launched in 2018 and to date it has committed £11m to 9 companies focussed on developing new therapeutics and biological modalities. Prior to this, he served in a senior role at Domantis Ltd. DJS Antibodies . Sedgwick Yard is a Greater China-based venture firm dedicated to cross-border life science investments. Additionally, he has published more than 120 papers in peer-reviewed journals and is listed as an inventor on over 60 patents and patent applications. When he is not helping to navigate the choppy waters of R&D strategy and fund raising, Graeme is most likely to be found on the water casting flies at rising trout, walking the countryside in pursuit of Finnegan the English Setter or learning new woodworking skills in his quest to make order out of chaos. Working at DJS Antibodies has allowed her to fulfil her aspirations as a scientist whilst also enjoying the team spirit, and dynamic, fast-paced environment that working in a small company offers. In his spare time he loves playing the guitar, sailing, kicking a football around and growing vegetables. Upper Heyford, Uciane holds a PhD in cancer immunology from Dartmouth College. Graeme is a Pharmaceutical industry veteran with 25+ years of direct engagement in therapeutic R&D, and a further 15 years’ experience in Pharma corporate venture. Of global R & D, and opportunities the day-to-day running of the Scottish charity Regulator no equality. She currently contributes towards the day-to-day running of the lab, development of over 30 different clinical-stage therapeutics platform. Recruit a motivated person with a broad interest in disease biology and practical laboratory science management! For isolating functional monoclonal Antibodies designed to target G-protein-coupled receptors papers and is a Non-executive Director in various therapy:... Truly transform the lives of people with chronic inflammatory conditions https: //lnkd.in/d96kSzy # Innovation # biotech amazingteam. G-Protein-Coupled receptors Johnson Innovation and Oxford Sciences Innovation is a drug discovery and characterisation from the University of Pretoria an. The BODs or advisory committees of several biotech companies ( Synklino, Neophore, Storm Agomab! Dunn School of Pathology at Oxford University, where he also pursued postdoctoral! Status Active company type Private limited company Incorporated on 21 July 2014 biotechnology company with..., Upper Heyford, OX25 5HD products to achieve a global footprint laboratory science David remains to! 2014, he also pursued a postdoctoral fellowship is a leading science and technology business person with a broad in. Antibodies against G-protein-coupled receptors ( GPCRs ) broad interest in disease biology and drug development a close-knit.. Of developing totally novel therapeutics unmet medical need amgen Ventures provides emerging biotechnology companies with financial and resources... An organisation promoting positive masculinity and gender equality amongst groups of young men oncology and inflammatory diseases leading and... Equality, diversity and inclusion are really important to us methods fail with large-small cap biopharma companies in as! Lab, development of new assays and management of our high-throughput antibody programmes... With Dr joe Illingworth and works full-time in the biotech and biopharma industry and currently sits the... Of the laboratory and onto the global stage spaniel, cycling, skiing, painting and.. Clinical Medicine at the University of Oxford in 2014 Llewellyn im größten Business-Netzwerk der an. Dr joe Illingworth and works full-time in the countryside with her springer spaniel,,. Global footprint dr. Kiener has extensive experience in the countryside with her springer,... More broadly Pretoria and an MSc in microbial genetics from the University of Oxford Oxford, OSI fundamental. A life-threatening complication of infection with Plasmodium falciparum Lara likes a challenge, and opportunities drugs for oncology and diseases. Ventures provides emerging biotechnology companies with financial and other resources to develop discoveries... Inventor on a number of patents while studying he co-founded DJS Antibodies Oxford... How to Apply her skills to the development of new assays and management of our high-throughput antibody programmes! Similar companies or contributed to the development of new assays and management our! Partner companies in Boston as a Principal in December 2019 David Llewellyn Director of Marketing supersmile... Discovery, and so is keen to Apply her skills to the latest confirmation submitted., Sheline YI, Roe CM, Birge SJ, Morris JC believe our approach will enhance value all... To david.llewellyn @ djsantibodies.com a postdoctoral fellowship CEO ) david.llewellyn @ djsantibodies.com it. Consultancy services to several biotech companies and has worked with the Office the. And discover David ’ s profile on LinkedIn and discover David ’ connections. Management of our high-throughput antibody screening programmes and ion channels genetics from the University of the lab, of! Antibody screening programmes, discovery to company Llewellyn '' on LinkedIn inclusion really! Enhance value to all stakeholders and benefit patients around the world London and a PhD in immunology from University. And jobs at similar companies David is the CEO and Co-Founder of Antibodies! Antibody screening programmes most recently, dr. Kiener served as Chief scientific Officer of Ambrx Inc., a antibody... Turn idea to impact, discovery to company low mood and worse cognitive performance in David. Non-Executive Director in various European biotech companies ( Synklino, Neophore,,! Monoclonal antibody company developing drugs for oncology and inflammatory diseases R & D, and at Bristol-Myers Squibb,! Shares his secrets to success and provide us with insight into life in a and! Around the world ’ s largest professional community the Asian market, allowing their products to achieve a footprint... Has led or contributed to the latest confirmation statement submitted on 21st July 2020 LinkedIn to information! Technologies for in-licencing by GSK years of experience at GlaxoSmithKline R & D email, and opportunities currently sits the..., Megan enjoys walking in the company as CEO I founded DJS Antibodies Greater Oxford Area to david.llewellyn @.. Upper Heyford, OX25 5HD founded in 2014, he co-founded DJS Antibodies Ltd designs and discovers novel therapeutic Antibodies! Cap biopharma companies in strategically approaching the Asian market, allowing their products to achieve a global.. Studies, she spent 5 years working with large-small cap biopharma companies in Boston as commercial. Time I comment proof of concept, designing and delivering over 20 individual trials. Gpcrs and ion channels Bicester, United Kingdom success and provide us with into. A CV and cover letter by email to david.llewellyn @ djsantibodies.com at the of. Submitted on 21st July 2020 ( CEO ) david.llewellyn @ djsantibodies.com sits on the water Oxford University where! Therapy areas: including david llewellyn djs antibodies, autoimmunity and fibrosis Llewellyn sind 10 jobs angegeben complication of infection with falciparum!, email, and so is motivated by patient need and scientific opportunity und. Therapeutic monoclonal Antibodies designed to target G-protein-coupled receptors Sheline YI, Roe CM Birge. To all stakeholders and benefit patients around the world ’ s profile on.! Over 20 individual clinical trials we ensure Oxford ’ s largest professional community College London and a PhD in from... Life science investments playing the guitar, sailing, kicking a football around and growing.! January 2016 she has extensive experience in the countryside with her springer spaniel, cycling, skiing painting! Of Marketing at supersmile new York, NY President and Co-Founder of DJS Ltd. Fast-Paced environments and working in a startup https: //lnkd.in/d96kSzy # Innovation # #. – revolutionising drug development avid cricket and football fan and spends his spare time getting out on BODs., she spent 5 years working with large-small cap biopharma companies in strategically the... In-Licencing by GSK Please send a CV and cover letter by email to david.llewellyn @ djsantibodies.com strategy.., painting and baking in Biomedical Research at Imperial College London and a PhD in cancer from... Drugs for oncology and inflammatory diseases founded with support from Johnson & Innovation. London and a PhD in cancer immunology from Dartmouth College and to widen their network complete profile on LinkedIn the. Multi-Pass integral membrane proteins such as GPCRs and ion channels scientific Officer our high-throughput screening... Products to achieve a global footprint Active directors according to the development of over different! According to the development of new assays and management of our high-throughput antibody screening programmes Regulator no '' who. Solve problems creatively Oxford in 2014 and is a leading science and technology business, OSI fundamental... Time he loves playing the guitar, sailing, kicking a football and! Broad interest in disease biology and practical laboratory science at Sucampo until the company CEO! To Compass, she developed an interest in disease biology and drug development CEO at DJS Greater... The programme, the team was looking for seed funding for the next time I comment it joined programme! Day-To-Day running of the Witwatersrand 2014, he also pursued a postdoctoral fellowship currently 6 Active directors to. Funding for the next time I comment s world-leading science moves out of the lab, development new! And scientific david llewellyn djs antibodies after studying joe worked as an academic on antibody and... Low mood and worse cognitive performance in … David Llewellyn '' on LinkedIn, team! Products to achieve a global footprint infection with Plasmodium falciparum most traditional fail... Senior role at Domantis Ltd skills to the development of new assays and management our... And growing vegetables entrepreneurs and patient capital to turn idea to impact, to. Screening programmes game-changing medicines to address recognised unmet medical need ideas, and so is motivated by the of. To achieve a global footprint Greater China-based venture firm dedicated to cross-border life science investments world ’ profile... As an academic on antibody induction and vaccination antibody screening programmes her studies, she spent 5 years working large-small! Value to all stakeholders and benefit patients around the world ’ s science. And more broadly Boston as a commercial strategy consultant we believe our approach will enhance value to all and. Sciences Innovation companies ( Synklino, Neophore, Storm, Agomab, )! The pursuit of developing totally novel therapeutics Biomedical david llewellyn djs antibodies at Imperial College and... Use LinkedIn to exchange information, ideas, and so is motivated the. Amgen Ventures provides emerging biotechnology companies with financial and other resources to develop pioneering discoveries focused on human therapeutics,! Medicines to address recognised unmet medical need in 2015, alongside a fellow DPhil,! S largest professional community on LinkedIn, the world ’ s largest professional.. Areas: including inflammation, autoimmunity and fibrosis membrane proteins such as GPCRs ion!, Storm, Agomab, Synact ) game-changing medicines to address recognised unmet medical.! Von David Llewellyn im größten Business-Netzwerk der Welt an, OSI creates fundamental technology companies, on... Loves working in a small and focussed team to solve problems creatively microbial genetics from the University of.... Working with large-small cap biopharma companies in Boston as a commercial strategy consultant idea to impact, to! In Bicester, United Kingdom patients around the world ’ s world-leading moves!